An interventional study of EHR-Embedded AKI Risk Score and EHR-Embedded AKI Risk Score with Best Practice Advisory in Acute Kidney Injury, Surgery Complications and Anesthesia, sponsored by University of California, San Francisco. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by University of California, San Francisco · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Acute Kidney Injury by University of California, San Francisco — 5 open to participants now, 6 under way, 1 of them phase 3. Acute Kidney Injury · University of California, San Francisco.
Among the 11 studies in Acute Kidney Injury by University of California, San Francisco, this one has the largest planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 with no phase, and was the 10th registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →5 of the 11 studies in Acute Kidney Injury by University of California, San Francisco are open now, in 2 countries. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States, Canada
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25,518 is above the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Median enrollment 55 across the 10 interventional studies, 2,000 across the 1 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, San Francisco is the lead sponsor of 2,172 studies on the registry; 370 are open to participants now.
Of its 269 completed or terminated interventional studies of FDA-regulated products, 203 (75%) have results posted.
2 of the studies in Acute Kidney Injury by University of California, San Francisco that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04705766University of California, San FranciscoKIDney Injury in Times of COVID-19 (KIDCOV) | 2027-03 |
| NCT07604662University of California, San FranciscoReal-Time Acute Kidney Injury Perioperative Prediction Clinical Trial | 2027-10-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Acute Kidney Injury by University of California, San Francisco, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This investigator-initiated, pragmatic trial evaluates whether displaying a machine learning (ML)- derived perioperative AKI risk score-alone or paired with an interruptive Best/Our Practice Advisory (BPA/OPA)-improves kidney-protective care and reduces kidney injury after non-obstetric surgery at UCSF. Approximately 75-100 attending anesthesiologists (clusters) are randomized 1:1:1 to: (a) Control (risk score hidden), (b) Score Only (visible preoperative AKI risk probability with passive KDIGO bundle recommendation), or (c) Score + BPA (visible risk plus interruptive KDIGO prompt for high-risk patients). CRNAs/residents follow their attending' s assignment. Adult inpatients (age ≥18) with expected overnight stay and eGFR ≥15 mL/min/1.73 m² are included; obstetrics, chronic dialysis, and kidney transplant patients are excluded. The underlying preoperative model was prospectively validated at UCSF and outperforms anesthesiologist risk estimation reported in the literature. The model was reviewed and approved by the AI Oversight Committee at UCSF. Primary endpoint is the continuous change in serum creatinine (mg/dL) from baseline to POD 1-2. Secondary outcomes include KDIGO-defined AKI, adherence to bundle elements (hemodynamics, balanced fluids, nephrotoxin avoidance, glycemic control), intraoperative hypotension time, fluid volumes, nephrotoxin exposure, perioperative hyperglycemia, length of stay, unplanned ICU transfer, readmission, dialysis, and in-hospital mortality. Data are obtained from the EHR; analysts are blinded. No direct subject interaction is planned; the investigators will request a waiver of patient consent. The study aims to demonstrate that ML-enabled, workflow-embedded decision support can safely and feasibly improve guideline concordant care and decrease early postoperative kidney injury.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive usual perioperative care with a placeholder blank display without the machine learning-derived acute kidney injury (AKI) risk score. The clinical decision support tool remains hidden in the electronic health record, and no alerts or recommendations related to the study are shown.
A machine learning-derived preoperative AKI risk score is displayed within the electronic health record for high-risk patients. A passive recommendation indicating that the patient may benefit from a KDIGO-based kidney-protective bundle is provided. The information is advisory only, and no interruptive alerts are used.
Device: EHR-Embedded AKI Risk Score
The machine learning-derived AKI risk score is displayed within the electronic health record for high-risk patients, accompanied by an interruptive Best Practice Advisory (BPA) that notifies providers that the patient may benefit from a KDIGO-based kidney-protective bundle. The alert is advisory only and does not mandate clinical actions.
Device: EHR-Embedded AKI Risk Score with Best Practice Advisory
A non-adaptive, machine learning-based clinical decision support tool integrated into the electronic health record that generates a preoperative probability of acute kidney injury (AKI) using routinely collected patient data. For patients identified as high risk, the tool displays the risk estimate to anesthesia providers without an accompanying Best Practice Advisory (BPA) recommending consideration of a KDIGO-based kidney-protective bundle. The intervention is advisory only, does not mandate clinical actions, and is designed to support provider decision-making within the existing clinical workflow.
Also known as: EHR-Embedded AKI Clinical Decision Support Tool
A non-adaptive, machine learning-based clinical decision support tool integrated into the electronic health record that generates a preoperative probability of acute kidney injury (AKI) using routinely collected patient data. For patients identified as high risk, the tool displays the risk estimate to anesthesia providers with an accompanying Best Practice Advisory (BPA) recommending consideration of a KDIGO-based kidney-protective bundle. The intervention is advisory only, does not mandate clinical actions, and is designed to support provider decision-making within the existing clinical workflow.
Also known as: EHR-Embedded AKI Clinical Decision Support Tool
Post-operative Change in Creatinine
Maximum continuous change in serum creatinine (mg/dL) from baseline to post-operative day 1-2
Time frame: From pre-operative baseline to 1-2 days post-operative level
Acute Kidney Injury
Acute Kidney Injury as defined by KDIGO
Time frame: Operation to Post-operative Day 7
KDIGO Bundle Adherence
Measurement of provider adherence to KDIGO components
Time frame: Intra-operative
Intra-Operative Time and Severity of Hypotension
Intra-Operative Time and Severity (meaning how far below the threshold) where patient is in hypotension, defined as systolic blood pressure \<90 mmHg and mean arterial pressure \<65 mmHg during surgery
Time frame: Intra-operative
Total intra-operative intravenous fluid volume administered (mL)
Provider administration of intravenous fluids during the intra-operative period, measured in milliliters (mL). Intravenous fluids include normal saline, lactated Ringer's, Plasma-Lyte, other balanced crystalloids, and colloid solutions such as albumin.
Time frame: Intra-operative
Length of Stay
Duration of patient admission in hospital in days
Time frame: Operation to Post-operative Day 180
Intra-operative Hyperglycemic Events
Number of intra-operative hyperglycemic events, defined as the number of recorded blood glucose measurements exceeding 180 mg/dL.
Time frame: Intra-operative
Intra-operative Nephrotoxin Exposure
Number of nephrotoxic medications administered intra-operatively and duration of intra-operative exposure
Time frame: Intra-operative
In-Hospital Mortality
Patient death while admitted in the hospital
Time frame: Operation to Post-operative Day 180
ICU Transfer and total time in the ICU
Any transfers to the ICU while admitted and the total time the patient spends in the ICU
Time frame: Postoperative
Hospital Readmission
Readmission back to a UCSF hospital following operation
Time frame: Operation to Post-operative Day 180
Dialysis Requirement
Patients requiring dialysis following surgery
Time frame: Operation to Post-operative Day 180
Dilution Corrected KDIGO AKI measurement (Stage 1 or higher)
Acute kidney injury (AKI) assessed using KDIGO creatinine criteria applied to dilution-corrected postoperative serum creatinine. Creatinine is corrected for hemodilution from perioperative fluid retention using the formula: Corrected Creatinine (mg/dL) = Measured Creatinine × (1 + Net Fluid Balance / Total Body Water) Where: * Net Fluid Balance (L) = Fluid inputs - urine output - blood loss - other outputs * Total Body Water (L) = 0.6 × weight (kg) for males; 0.5 × weight (kg) for females
Time frame: AKI is defined per KDIGO as corrected creatinine increase ≥0.3 mg/dL within 48 hours or ≥1.5× baseline within 7 days. This measure captures "hidden AKI" - kidney injury masked by fluid dilution that would be missed using standard uncorrected creatinine.
Total intra-operative packed red blood cells administered (units transfused)
Provider administration of packed red blood cells during the intra-operative period, measured as total units transfused.
Time frame: intraoperative
Total intra-operative fresh frozen plasma administered (units transfused)
Provider administration of fresh frozen plasma during the intra-operative period, measured as total units transfused.
Time frame: intraoperative
Total intra-operative platelets administered (units transfused)
Provider administration of platelets during the intra-operative period, measured as total units transfused.
Time frame: intraoperative
Total intra-operative cryoprecipitate administered (units transfused)
Provider administration of cryoprecipitate during the intra-operative period, measured as total units transfused.
Time frame: intraoperative
Plan to share: No
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 12 months is below that.
Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →